Ipilimumab-induced perforating colitis

Journal of Clinical Gastroenterology

Volumn 47, Issue 9, 2013, Pages 781-785

  Mitchell, Kisha A ^a   Kluger, Harriet ^b   Sznol, Mario ^b   Hartman, Douglas J ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Anti CTLA 4 therapy; Autoimmune colitis; Colectomy; Ipilimumab; Perforating colitis

Indexed keywords

BUDESONIDE; EYE DROPS; IPILIMUMAB; LOPERAMIDE; METHYLPREDNISOLONE; PREDNISONE; PROCHLORPERAZINE;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABDOMINAL RADIOGRAPHY; ABDOMINAL WALL; ADIPOSE TISSUE; ADULT; AGED; APPENDECTOMY; ARTICLE; CASE REPORT; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE; COLITIS; COLON BIOPSY; COLON MUCOSA; COLON PERFORATION; COLON RESECTION; COMPUTER ASSISTED TOMOGRAPHY; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG INFUSION; EDEMA; ERYTHEMA; FATIGUE; FEMALE; FEVER; HOSPITAL ADMISSION; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; ILEOSTOMY; INFLAMMATORY INFILTRATE; INTESTINE METAPLASIA; INTESTINE PERFORATION; INTRAOPERATIVE PERIOD; LAMINA PROPRIA; LOOSE FECES; LYMPHOCYTOSIS; MALAISE; MALE; METASTATIC MELANOMA; MYELOID PROGENITOR CELL; NAUSEA; PANETH CELL; PERITONITIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PRURITUS; PUS; RESPIRATORY FAILURE; SEPSIS; SIGMOIDOSCOPY; STEROID THERAPY; STOMACH TUBE; THORAX RADIOGRAPHY; TOTAL COLON RESECTION; TRANSVERSE COLON; ULCER; VOMITING;

AGED; ANTIBODIES, MONOCLONAL; COLECTOMY; COLITIS; DIARRHEA; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS;

EID: 84884671560     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31828f1d51     Document Type: Article

References (13)

1. Egen JG, Kuhns MS, Allison JP. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002;3:611-618.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517-2526.
3. Wolchok JD, Weber JS, Hamid O, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: A retrospective analysis of HLA subtype from four trials. Cancer Immun. 2010;10:9.
4. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyteassociated antigen 4. J Clin Oncol. 2006;24:2283-2289.
5. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008;13(suppl 4):2-9.
6. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264.
7. Johnston RL, Lutzky J, Chodhry A, et al. Cytotoxic Tlymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci. 2009;54:2538-2540.
8. Berman D, Parker SM, Siegel J, et al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010;10:11.
9. Minor DR, Chin K, Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immunerelated colitis. Cancer Biother Radiopharm. 2009;24:321-325.
10. Oble DA,Mino-Kenudson M, Goldsmith J, et al. Alpha-CTLA-4 mAb-associated panenteritis: A histologic and immunohistochemical analysis. Am J Surg Pathol. 2008;32:1130-1137.
11. Mpofu S, Mpofu CM, Hutchinson D, et al. Steroids, nonsteroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions. Ann Rheum Dis. 2004;63:588-590.
12. Sharma R, Gupta KL, Ammon RH, et al. Atypical presentation of colon perforation related to corticosteroid use. Geriatrics. 1997;52:88-90.
13. Kenney B, Loeser C, Sznol M, et al. Ipilimumab induced enterocolitis: A clinico-pathologic study. Mod Pathol. 2010;23:151A.